Format

Send to

Choose Destination
Cancer Biol Ther. 2015;16(10):1471-85. doi: 10.1080/15384047.2015.1071729. Epub 2015 Jul 15.

Small molecule inhibitors of IRES-mediated translation.

Vaklavas C1,2, Meng Z3,4, Choi H1,2,5, Grizzle WE1,6, Zinn KR1,2,6, Blume SW1,2,3.

Author information

1
a Comprehensive Cancer Center; University of Alabama at Birmingham ; Birmingham , AL USA.
2
b Department of Medicine , Division of Hematology / Oncology; University of Alabama at Birmingham ; Birmingham , AL USA.
3
c Department of Biochemistry and Molecular Genetics; University of Alabama at Birmingham ; Birmingham , AL USA.
4
d Current address: Analytical Development Department; Novavax Inc. ; Gaithersburg , MD USA.
5
e Current address: Department of Pediatrics; Seoul National University Bundang Hospital; Gyeonggi-do , Korea.
6
f Department of Pathology; University of Alabama at Birmingham ; Birmingham , AL USA.

Abstract

Many genes controlling cell proliferation and survival (those most important to cancer biology) are now known to be regulated specifically at the translational (RNA to protein) level. The internal ribosome entry site (IRES) provides a mechanism by which the translational efficiency of an individual or group of mRNAs can be regulated independently of the global controls on general protein synthesis. IRES-mediated translation has been implicated as a significant contributor to the malignant phenotype and chemoresistance, however there has been no effective means by which to interfere with this specialized mode of protein synthesis. A cell-based empirical high-throughput screen was performed in attempt to identify compounds capable of selectively inhibiting translation mediated through the IGF1R IRES. Results obtained using the bicistronic reporter system demonstrate selective inhibition of second cistron translation (IRES-dependent). The lead compound and its structural analogs completely block de novo IGF1R protein synthesis in genetically-unmodified cells, confirming activity against the endogenous IRES. Spectrum of activity extends beyond IGF1R to include the c-myc IRES. The small molecule IRES inhibitor differentially modulates synthesis of the oncogenic (p64) and growth-inhibitory (p67) isoforms of Myc, suggesting that the IRES controls not only translational efficiency, but also choice of initiation codon. Sustained IRES inhibition has profound, detrimental effects on human tumor cells, inducing massive (>99%) cell death and complete loss of clonogenic survival in models of triple-negative breast cancer. The results begin to reveal new insights into the inherent complexity of gene-specific translational regulation, and the importance of IRES-mediated translation to tumor cell biology.

KEYWORDS:

IGF1R; Internal ribosome entry site (IRES); c-Myc; gene-specific translational regulation; triple-negative breast cancer

PMID:
26177060
PMCID:
PMC4846101
DOI:
10.1080/15384047.2015.1071729
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center